# Anokion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anokion

- Industry: Biotechnology
- Headquarters: Ecublens, Switzerland
- Website: www.anokion.com
- Total disclosed funding: $77M
- Latest round: Series B (Sep 11, 2019)
- Investors on record: 4

## About

Anokion SA is a biopharmaceutical company specializing in innovative immune tolerance therapies for autoimmune diseases, utilizing proprietary engineered proteins to provide targeted treatment solutions.Founded in 2010, Anokion SA is based in Ecublens, Switzerland. The company specializes in immune tolerance therapies and has undergone development to streamline its therapeutic offerings. The current CEO is Deb Geraghty, and the company was founded by Stephan Kontos. Anokion has secured a total of USD 35.00 mn through funding, with the latest investment round in October 2022 led by Pfizer Venture Investments, which aimed to enhance the company’s clinical development efforts.Anokion specializes in innovative immune tolerance therapies aimed at treating autoimmune diseases. The company's core product offerings are centered around its proprietary immune tolerance platform, which utilizes engineered proteins, or antigens, to deliver precise and targeted therapies that minimize the side effects associated with traditional broad immunosuppressive treatments. This platform has a wide potential application across various clinical uses, addressing conditions such as celiac disease and multiple sclerosis. Anokion's target clientele includes healthcare providers, research institutions, and pharmaceutical partners within the biopharmaceutical industry, primarily focusing on markets in North America and Europe. These products are designed for healthcare settings, with the objective of significantly improving patient outcomes in autoimmune disease management.Anokion’s revenue model is structured around partnerships with biopharmaceutical companies and healthcare providers for the development and commercialization of its immune tolerance therapies. Transactions typically occur through collaborative agreements that may involve milestone payments and royalties tied to successful clinical outcomes. The company’s flagship products, such as those targeting celiac disease and multiple sclerosis, are developed under these partnership frameworks, facilitating both B2B transactions with pharmaceutical partners and potential licensing agreements. The revenue generated is linked to the progress of these therapeutics through clinical trials and subsequent market access, providing a structured financial return based on performance metrics established in each partnership.In October 2022, Anokion SA secured USD 35.00 mn in venture funding led by Pfizer Venture Investments, which will be utilized to support the clinical development of the Phase 2 clinical program of KAN-101. The company aims to expand its product offerings and enhance therapeutic developments in the autoimmune disease space. Anokion is also focusing on broadening its market presence in North America and Europe, seeking to reach more healthcare providers and institutions by 2024.

## Funding rounds

- Series B, Sep 11, 2019, $40M — Versant Ventures, Novartis Venture Fund, Novo Holdings, Bristol-Myers Squibb Company
- Series A, May 5, 2014, $37M — Versant Ventures, Novartis Venture Fund, Novo Holdings

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Novo Holdings — Series A, Series B
- Bristol-Myers Squibb Company — Series B